Clinical trials
Liver Cirrhosis, Alcoholic clinical trials
Below are recruiting liver cirrhosis, alcoholic clinical trials, each written for real people, not researchers. We’re tracking 97 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07452744Enrolling by invitation
Picroliv for non-alcoholic fatty liver disease
This study tests a plant-based medicine called Picroliv for people with non-alcoholic fatty liver disease (NAFLD). It aims to see if it is safe and can reduce fat in the liver.
Chandigarh, ChandigarhAges 18–60 - NCT06338215Recruiting
Moderate drinking vs. abstention advice for adults
This study compares two approaches for adults who drink regularly: advice on drinking in moderation vs. advice to stop drinking entirely. The goal is to see which approach better prevents major diseases and early death over time.
Pamplona, NavarreAges 50–75 - NCT03224949Recruiting
Study comparing fatty liver types and healthy livers
This study compares liver samples and blood tests from people with alcohol-related fatty liver disease, alcohol-related hepatitis, and cirrhosis (including some with liver cancer) against healthy controls. It aims to better tell these liver conditions apart and understand what is different between them.
Cleveland, OhioAges 18–75 - NCT05433948Enrolling by invitation
Testing ways to diagnose mild brain changes in liver disease
This study looks at how well simple brain tests can detect early (minimal) thinking changes related to liver cirrhosis. It may help doctors spot these changes sooner and diagnose the condition more accurately.
EsbjergAges 18–90 - NCT07610837RecruitingPhase 2
Testing AZD2389 for fatty liver disease with scarring
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
Chandler, ArizonaAges 18 years+ - NCT06920043RecruitingPhase 2
Study of a new drug for cirrhosis from fatty liver disease
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
Chandler, ArizonaAges 18–75 - NCT06814600Recruiting
Fatty liver study in inflammatory bowel disease patients
This study checks how often people with Crohn's or ulcerative colitis also have fatty liver disease. It uses a painless scan to measure liver stiffness and fat. If you have IBD, you may join to help researchers learn about the link between these conditions.
BrusselsAges 18 years+ - NCT07221188RecruitingPhase 3
Efimosfermin alfa for liver scarring in MASH
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Arcadia, CaliforniaAges 18–75 - NCT07221227RecruitingPhase 3
Testing a new drug for MASH with moderate scarring
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Chandler, ArizonaAges 18–75 - NCT03811236Recruiting
Test cold exposure to activate body fat and reduce liver fat
This study tests whether controlled cold exposure can activate “brown fat” and affect liver fat buildup. It may help people with excess liver fat, measured on imaging, but it has several health and medication exclusions.
ViennaAges 18–50 - NCT05028829RecruitingPhase 2
Atorvastatin to lower liver cancer risk in people with liver scarring
This trial tests whether atorvastatin (a cholesterol medicine) can lower the chance of liver cancer (HCC) in people with advanced liver scarring or cirrhosis. Participants are compared to placebo (inactive pill) while researchers track safety and cancer risk.
Boston, MassachusettsAges 18 years+ - NCT05305287RecruitingPhase 4
Study how energy use in the liver works in people with fatty liver and diabetes
This trial measures how your liver cells use energy (mitochondrial function) in people with type 2 diabetes and fatty liver. It aims to better understand what is happening in the liver and how disease severity may relate to diabetes.
San Antonio, TexasAges 18–80 - NCT05541601Recruiting
Study to detect liver cancer early in people with cirrhosis
This study follows people with cirrhosis to see how best to detect liver cancer early. If you qualify, you may receive regular monitoring that could help find liver cancer sooner, when treatment is more likely to work.
Oxford, OxfordshireAges 18–100 - NCT06354088RecruitingPhase 1
Study of alpelisib for insulin resistance
This study tests a single dose of a drug called alpelisib (a PI3K inhibitor) to see how it affects insulin and blood sugar in people who are either insulin sensitive or insulin resistant. The goal is to understand why some people become resistant to insulin, which may help find new treatments for diabetes and related conditions.
New York, New YorkAges 18–70 - NCT06477146RecruitingPhase 2
Milk thistle for fatty liver in children and young adults
This trial tests whether milk thistle can help children and young adults with non-alcoholic fatty liver disease (NAFLD), a condition where fat builds up in the liver unrelated to alcohol use. It aims to see if the supplement can lower liver enzymes and improve liver health.
Cleveland, OhioAges 9–22 - NCT06707129Recruiting
New criteria to see if NASH liver scarring has reversed
This study is creating better ways to measure if liver scarring from NASH (a type of fatty liver disease) has improved. It may help doctors know if treatments are working.
Beijing, Beijing MunicipalityAges 18–70 - NCT07403604RecruitingPhase 1
Lowering Insulin to Reduce Fat Buildup in the Liver
This study tests if lowering insulin levels can reduce fat buildup in the liver for people with a fatty liver condition called MASLD. It's looking for adults who are overweight and have early signs of insulin resistance but not diabetes.
New York, New YorkAges 18–65 - NCT07358546RecruitingPhase 1
Test of efimosfermin alfa in adults with liver problems
This trial is for adults with liver cirrhosis (scarring) who have moderate to severe liver impairment. It studies how the body handles a new medicine called efimosfermin alfa, to see if it could be a safe treatment option. You may be able to join if your liver function is stable and you fall into a specific Child-Pugh class.
Rialto, CaliforniaAges 18–70 - NCT05956379Enrolling by invitation
Exercise and monitoring study for chronic hepatitis B with fatty liver
This study follows adults with chronic hepatitis B who also have fatty liver and tests an exercise approach to see how it affects liver health. You may be followed over time and helped with an exercise plan if you qualify.
Taipei, Zhongzheng Dist.Ages 18–70 - NCT06778317Recruiting
Blood test to predict liver cancer in cirrhosis patients
This trial tests if a simple blood test can help predict who with cirrhosis might develop liver cancer, so doctors can monitor and treat those patients earlier.
Vandœuvre-lès-NancyAges 18 years+ - NCT07058155RecruitingPhase 4
TIPS and weight-loss surgery for liver disease with high blood pressure
This trial tests if doing a TIPS procedure (to lower blood pressure in the liver) before weight-loss surgery (sleeve gastrectomy) helps people with advanced liver disease. It's for those who have cirrhosis and very high blood pressure in the liver, and who qualify for sleeve gastrectomy.
Cleveland, OhioAges 18–70 - NCT06632457RecruitingPhase 3
Survodutide for NASH/MASH cirrhosis: a phase 3 trial
This study tests an investigational drug called survodutide for people with a type of fatty liver disease (NASH or MASH) that has progressed to cirrhosis. The goal is to see if it can improve liver health.
Peoria, ArizonaAges 18 years+ - NCT06676813Recruiting
Fasting every other day for fatty liver disease
This study tests whether fasting every other day (alternate day fasting) can help reverse fatty liver disease (NASH/MASH) when added to standard medical care. It is for people with fatty liver and some liver scarring, who are not on weight loss medications and do not have diabetes that is poorly controlled.
DelhiAges 18–65 - NCT06308757Recruiting
Studying a very low calorie keto diet for fatty liver disease with scarring
This trial tests whether a very low calorie ketogenic diet (a strict low-carb, high-fat diet) can help people with non-alcoholic steatohepatitis (NASH) who have liver scarring. Participants will follow this diet for a year and have two liver biopsies to see if their liver health improves.
BolognaAges 18 years+
Hear when a new Liver Cirrhosis, Alcoholic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cirrhosis, alcoholic?
- Yes. Clin2 currently lists 97 recruiting liver cirrhosis, alcoholic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cirrhosis, alcoholic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cirrhosis, alcoholic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.